上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2014年
21期
24-27
,共4页
dolutegravir%整合酶链转移抑制剂%不良反应
dolutegravir%整閤酶鏈轉移抑製劑%不良反應
dolutegravir%정합매련전이억제제%불량반응
dolutegravir%integrase strand transfer inhibitor%adverse reactions
dolutegravir是第二代整合酶链转移抑制剂。与第一代整合酶链转移抑制剂相比，dolutegravir具有更高的耐药发展屏障，可一天1次给药。对已产生对拉替拉韦和elvitegravir耐药的人免疫缺陷病毒感染患者，仍可使用dolutegravir，但用药频率调整为一天2次。dolutegravir用于肝、肾功能损害患者时不需剂量调整。在临床试验中，dolutegravir治疗的最常见不良反应是失眠和头痛，发生率均为2%~3%。作为一种新的整合酶链转移抑制剂， dolutegravir具有疗效显著、耐受性好的特点。
dolutegravir是第二代整閤酶鏈轉移抑製劑。與第一代整閤酶鏈轉移抑製劑相比，dolutegravir具有更高的耐藥髮展屏障，可一天1次給藥。對已產生對拉替拉韋和elvitegravir耐藥的人免疫缺陷病毒感染患者，仍可使用dolutegravir，但用藥頻率調整為一天2次。dolutegravir用于肝、腎功能損害患者時不需劑量調整。在臨床試驗中，dolutegravir治療的最常見不良反應是失眠和頭痛，髮生率均為2%~3%。作為一種新的整閤酶鏈轉移抑製劑， dolutegravir具有療效顯著、耐受性好的特點。
dolutegravir시제이대정합매련전이억제제。여제일대정합매련전이억제제상비，dolutegravir구유경고적내약발전병장，가일천1차급약。대이산생대랍체랍위화elvitegravir내약적인면역결함병독감염환자，잉가사용dolutegravir，단용약빈솔조정위일천2차。dolutegravir용우간、신공능손해환자시불수제량조정。재림상시험중，dolutegravir치료적최상견불량반응시실면화두통，발생솔균위2%~3%。작위일충신적정합매련전이억제제， dolutegravir구유료효현저、내수성호적특점。
Dolutegravir is the second-generation integrase strand transfer inhibitor, and it has higher barrier for resistance compared with raltegravir and elvitegravir and can be used once daily. Dolutegravir can be still administered to the patients who have HIV resistance to raltegravir and elvitegravir, however, its dosing frequency has to be changed to twice a day. This drug shares the mechanism of action with raltegravir and elvitegravir and dosage adjustments are not necessary for the patients with renal and hepatic impairment. The most common adverse reactions seen with dolutegravir in clinical trials are insomnia and headache, occurring in only 2%to 3%of patients. In conclusion, dolutegravir has characteristics of signiifcant efifcacy and good tolerance.
